|
[1]ROMERO-GMEZ M, ZELBER-SAGI S, TRENELL M.Treatment of NAFLD with diet, physical activity and exercise[J].J Hepatol, 2017, 67 (4) :829-846.
|
|
[2]YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al.Global burden of NAFLD and NASH:trends, predictions, risk factors and prevention[J].Nat Rev Gastroenterol Hepatol, 2017.[Epub ahead of print]
|
|
[3]FAN JG, KIM SU, WONG VW.New trends on obesity and NAFLDin Asia[J].J Hepatol, 2017, 67 (4) :862-873.
|
|
[4]GU D, REYNOLDS K, WU X, et.al.Prevalence of the metabolic syndrome and overweight among adults in China[J].Lancet, 2005, 365 (9468) :1398-1405.
|
|
[5]FARRELL GC, LARTER CZ.Nonalcoholic fatty liver disease:from steatosis to cirrhosis[J].Hepatology, 2006, 43 (2 Suppl 1) :s99-s112.
|
|
[6]DOULBERIS M, KOTRONIS G, GIALAMPRINOU D, et al.Non-alcoholic fatty liver disease:an update with special focus on the role of gut microbiota[J].Metabolism, 2017, 71:182-197.
|
|
[7]DEGASPERI E, COLOMBO M.Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease[J].Lancet Gastroenterol Hepatol, 2016, 1 (2) :156-164.
|
|
[8]WONG VW, CHITTURI S, WONG GL, et al.Pathogenesis and novel treatment options for non-alcoholic steatohepatitis[J].Lancet Gastroenterol Hepatol, 2016, 1 (1) :56-67.
|
|
[9] DULAI PS, SINGH S, PATEL J, et al.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis[J].Hepatology, 2017, 65 (5) :1557-1565.
|
|
[10]WESOLOWSKI SR, KASMI KC, JONSCHER KR, et al.Developmental origins of NAFLD:a womb with a clue[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (2) :81-96.
|
|
[11]TILG H, MOSCHEN AR, RODEN M.NAFLD and diabetes mellitus[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (1) :32-42.
|
|
[12]ADAMS LA, ANSTEE QM, TILG H, et.al.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J].Gut, 2017, 66 (6) :1138-1153.
|
|
[13]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology, 2017.[Epub ahead of print]
|
|
[14]European Association for the Study of the Liver (EASL) , EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol, 2016, 64 (6) :1388-1402.
|
|
[15]DOYCHEVA I, WATT KD, ALKHOURI N.Nonalcoholic fatty liver disease in adolescents and young adults:the next frontier in the epidemic[J].Hepatology, 2017, 65 (6) :2100-2109.
|
|
[16]FAN JG, CHITTURI S.Hepatitis B and fatty liver:causal or coincidental?[J].J Gastroenterol Hepatol, 2008, 3 (5) :679-681.
|
|
[17]LIEW PL, LEE WJ, LEE YC, et al.Hepatic histopathology of morbid obesity:concurrence of other forms of chronic liver disease[J].Obes Surg, 2006, 16 (12) :1584-1593.
|
|
[18]SHI JP, FAN JG, WU R, et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J].J Gastroenterol Hepatol, 2008, 23 (9) :1419-1425.
|
|
[19]MACHADO MV, OLIVEIRA AG, CORTEZ-PINTO H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients[J].JGastroenterol Hepatol, 2011, 26 (9) :1361-1367.
|
|
[20]JOO EJ, CHANG Y, YEOM JS, et al.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease:a cohort study[J].Hepatology, 2017, 65 (3) :828-835.
|
|
[21]BRUNT EM, JANNEY CG, di BISCEGLIE AM, et al.Nonalcoholic steatohepatitis:a proposal for grading and staging the histological lesions[J].Am J Gastroenterol, 1999, 94 (9) :2467-2474.
|
|
[22]KLEINER DE, BRUNT EM, van NATTA M, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Nonalcoholic Steatohepatitis Clinical Research Network[J].Hepatology, 2005, 41 (6) :1313-1321.
|
|
[23]BEDOSSA P, FLIP Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology, 2014, 60 (2) :565-575.
|
|
[24]BEDOSSA P, POITOU C, VEYRIE N, et al.Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients[J].Hepatology, 2012, 56 (5) :1751-1759.
|
|
[25]ALKHOURI N, de VITO R, ALISI A, et al.Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease[J].J Hepatol, 2012, 57 (6) :1312-1318.
|
|
[26]RATZIU V, HARRISON SA, FRANCQUE S, et al.Elafibranor, an agonist of the peroxisome proliferator-activated receptor-αand-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J].Gastroenterology, 2016, 150 (5) :1147-1159.
|
|
[27]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :a multicentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965.
|
|
[28]ROTMAN Y, SANYAL AJ.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J].Gut, 2017, 66 (1) :180-190.
|
|
[29]VIOLI F, CANGEMI R.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J].N Engl J Med, 2010, 363 (12) :1185-1186.
|
DownLoad: